Next Phase Newsletter

An investor and venture builder based in the USA invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused Venture Capital and Growth Equity firm currently manages ~$1 billion, providing $15-$50 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital firm based in Canada with additional offices in USA manages over $500M AUM and has invested over $450M in more than 100 companies. With their recent fund closed in 2021, the firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada.

The firm invests primarily in therapeutics and  medical devices, and consumer health technologies. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data. That said, the firm is open to earlier stage, pre-clinical companies with strong validation. The firm is agnostic in terms of modalities.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global biopharmaceutical company with strong interest to invest and collaborate with clinical & early-stage life science companies has significant experience and expertise in conducting drug development and clinical trials in Asia and China, and they are looking to leverage that to partner up with clinical-stage companies. The firm is open to equity investment, licensing-in, co-development and other partnership models. In terms of equity investments, the firm typically engages in seed to series A investment rounds. The initial check size ranges from $1~ 3M with the possibility for follow-on rounds. The firm is generally interested in companies based in the US and Europe and is open to both leading and co-investing.

The firm is interested in therapeutics and medical devices that provide solutions to unmet needs and have strong market potential in Asia and China. Interested indications include chronic, inflammation and aging-related diseases, oncology, and rare diseases. The firm is also interested in rare diseases as long as there are huge unmet needs. The firm is most interested in therapeutics assets that are in Phase I or Phase II clinical stage but can be flexible if the technology is a good fit.

There are no specific requirements for the company’s management team. The firm might consider a board seat on a case-by-case basis. The firm has a strong presence in China and Asia and is willing to support companies with their expertise and experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment group that was founded by a family office has teams based in USA and Asia. The group is actively seeking new investments in the life sciences. The group invests broadly in therapeutics and digital health. The investment size will vary and typically it ranges from single to double digit millions. The group has no set number of allocations over the next 6-9 months.

In life sciences, the firm’s US team is looking for new investments in digital health and therapeutics. For therapeutics, the group is modality and indication agnostic. The group invests in both preclinical and clinical stage companies. The group is open to lead or syndicate with other investors.

The firm invests in privately-held life science companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm was founded in 2020 and is based in San Francisco, CA. The firm is expecting to close their first fund this year, targeting $100M. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Israel, Japan, Europe, Asia, etc.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech-enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Based in Boston and founded in 2006, a venture capital firm is currently investing from its fourth fund of $300 million closed in 2019. The firm typically is the lead or co-lead in the first institutional or Series A rounds in early-stage companies in the enterprise information technology (IT) space, including digital health. The firm’s equity investment size ranges from $3-7 million. The firm is most active on the US East Coast and would consider opportunities from across the US. The firm plans to make 5-7 new investments in the following year.

Within digital health, the firm is seeking systems, technologies, and services that support clinical delivery to improve outcomes and efficiency of clinical care. The firm is not interested in consumer-facing products, genomic analytics, or life sciences software – the focus is healthcare IT and services. The firm is looking for innovations that have demonstrated product-market fit in the form of recurring annual revenue of $1M or more. Pre-revenue companies may be considered if there is a strong fit with its investment thesis. When it comes to digital health investments, the firm often syndicates with strategic co-investors who understand the risks in the healthcare system, such as healthcare providers and payers.

The firm is looking for competent and experienced management teams with sector expertise. The firm brings in real-world experience, industry knowledge and networks, and company-building skills to its portfolio companies. The firm takes a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.